Amendment to the Claims

- (Currently amended) A method for detecting antithrombin III (AT) in a sample that may contain an interfering factor, the interfering factor being a drug, the method comprising:
- (a) providing a reaction mixture by contacting the sample with a first reagent R1 comprising an excess of AT binding partner under conditions wherein the AT binding partner essentially does not interact with AT but a portion of the AT binding partner interacts with the interfering factor such that the interfering factor is no longer available to interfere with the AT and a first free fraction of the AT binding partner remains,
- (b) adding to the reaction mixture a second reagent R2 for a first determination of the said first free fraction of the AT binding partner,
- (c) changing the conditions of the reaction mixture by adding to the reaction mixture a third reagent R3 such that at least a portion of said first free fraction of the AT binding partner interacts with AT, such that a second free fraction of the AT binding partner remains.
- (d) conducting a second determination of the <u>second</u> free fraction of the AT binding partner in the reaction mixture, wherein the determination comprises using the reagent R2, and
- (e) determining the AT content in the sample from the difference between the first and second determinations of the <u>first and second</u> free <u>fraction fractions</u> of the AT binding partner.
 - 2. (Original) The method of claim 1 wherein the AT binding partner is thrombin.
 - 3. (Withdrawn) The method of claim 1 wherein the AT binding partner is factor Xa.
- (Original) The method of claim 1 wherein the second reagent R2 comprises a chromogenic substrate.
- (Withdrawn) The method of claim 1 wherein the second reagent R2 comprises an antibody for determining the free AT binding partner.
- (Original) The method of claim 1 wherein the third reagent R3 comprises an accelerator of the interaction between AT and the AT binding partner.

- 7. (Original) The method of claim 6 wherein the accelerator is heparin.
- (Original) The method of claim 1 wherein the first reagent R1 further comprises an antagonist for an accelerator of the interaction between AT and the AT binding partner.
- (Original) The method of claim 8 wherein the first reagent R1 comprises polybrene.
- (Original) The method of claim 1 wherein the third reagent R3 further comprises an additional AT binding partner.
- 11. (Original) The method of claim 1 wherein the determination of the AT binding partner comprises a kinetic determination.
 - 12. (Cancelled)
 - 13. (Cancelled)
 - 14. (Cancelled)
 - 15. (Cancelled)